In particular, ATM/ATR-mutated patients have a profound enrichment of FA and HR pathway aberrations, and these NSCLC patients had more mutational burdens, higher MSI, and worse prognosis. The gene discussed is ATM; the disease is non-small cell lung carcinoma.